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Potential Utility of Cardiorenal Biomarkers for Prediction and
Prognostication of Worsening Renal Function in Acute
Heart Failure
YU HORIUCHI, MD,1,2 NICHOLAS WETTERSTEN, MD,1 DIRK J. VAN VELDHUISEN, MD,3 CHRISTIAN MUELLER, MD,4
GERASIMOS FILIPPATOS, MD,5 RICHARD NOWAK, MD,6 CHRISTOPHER HOGAN, MD,7 MICHAEL C. KONTOS, MD,8
€
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Kansas; Gottingen, Germany; Brooklyn, New York; Lviv, Ukraine; Valencia and Madrid, Spain; Naples and Pisa, Italy, and Dublin, Ireland.

ABSTRACT
Background: Multiple different pathophysiologic processes can contribute to worsening renal function
(WRF) in acute heart failure.
Methods and Results: We retrospectively analyzed 787 patients with acute heart failure for the relationship between changes in serum creatinine and biomarkers including brain natriuretic peptide, high sensitivity cardiac troponin I, galectin 3, serum neutrophil gelatinase-associated lipocalin, and urine neutrophil
gelatinase-associated lipocalin. WRF was defined as an increase of greater than or equal to 0.3 mg/dL or
50% in creatinine within first 5 days of hospitalization. WRF was observed in 25% of patients. Changes in
biomarkers and creatinine were poorly correlated (r  0.21) and no biomarker predicted WRF better than
creatinine. In the multivariable Cox analysis, brain natriuretic peptide and high sensitivity cardiac troponin
I, but not WRF, were significantly associated with the 1-year composite of death or heart failure hospitalization. WRF with an increasing urine neutrophil gelatinase-associated lipocalin predicted an increased risk
of heart failure hospitalization.
Conclusions: Biomarkers were not able to predict WRF better than creatinine. The 1-year outcomes were
associated with biomarkers of cardiac stress and injury but not with WRF, whereas a kidney injury biomarker may prognosticate WRF for heart failure hospitalization. (J Cardiac Fail 2020;00:1 9)
Key Words: Biomarkers, worsening renal function, acute heart failure, prognosis.

Acute kidney dysfunction is frequently observed in
patients with acute heart failure (AHF). This has been

termed worsening renal function (WRF), usually defined as
a deterioration in kidney function reflected by increasing
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creatinine and decreasing glomerular filtration rate
(GFR).1 5 WRF has been variably associated with worse,
neutral, or even improved outcomes.1 5 This variability is
likely a product of different pathophysiologic processes
driving alterations in renal function and potentially depends
on whether acute tubular injury (ATI) is occurring.5 Studies
have recently shown WRF in the setting of aggressive and
effective decongestive therapy in AHF is a result of benign
functional changes in the GFR and not associated with ATI
or a poor prognosis.2 5 Although these studies focused on
evaluating kidney specific biomarkers, a more global
assessment of systemic processes that may affect kidney
function, such as hemodynamic changes, inflammation,
neurohormonal activation, and immune-mediated damage,
may give improved insight into the causes and prognostic
outcomes of WRF.6
The Acute Kidney Injury Neutrophil gelatinase-associated lipocalin (NGAL) Evaluation of Symptomatic heart
faIlure Study (AKINESIS) is one of the largest international
multicenter prospective cohort studies specifically designed
to evaluate cardiorenal syndrome (CRS) in patients with
AHF.7 In addition to serial measurements of serum NGAL
(sNGAL) and urine NGAL (uNGAL) for the assessment of
ATI, other biomarkers including B-type natriuretic peptide
(BNP), high sensitivity cardiac troponin I (hscTnI), and
galectin 3 (Gal3) were analyzed from stored serum
samples.8 10 These biomarkers can reflect different detrimental pathophysiologic processes in CRS, including congestion, myocardial damage, myocardial fibrosis, kidney
injury and fibrosis, and systemic inflammation.11 16 In this
study, we investigated the contribution of different pathophysiologic processes as reflected by biomarkers for the
risk of developing WRF, and their prognostic significance
in relation to WRF outcomes in patients with AHF.
Methods
Study Population

We retrospectively analyzed patients in AKINESIS,
which has been previously described.7 Briefly, from January
2011 through September 2013, 927 patients were enrolled at
16 sites in the United States and Europe. Patients had to
have 1 or more signs or symptoms of HF, including dyspnea
on exertion, rales or crackles, galloping heart rhythm, jugular venous distention, orthopnea, paroxysmal nocturnal dyspnea, using more than 2 pillows to sleep, fatigue, edema,
frequent coughing, a cough that produces mucous or bloodtinged sputum, or a dry cough when lying flat. Patients
must have received or planned treatment with intravenous
diuretics. Exclusion criteria were (1) acute coronary syndrome, (2) patients on dialysis or initiation was planned
during the current hospitalization, (3) major organ transplantation, (4) enrolment in a drug treatment study within
the past 30 days or patients who had already enrolled in this
study, or (5) were pregnant or belonging to an institutional
review board determined vulnerable population. In the
current analysis, 6 patients lacked creatinine measurements,

29 patients lacked BNP measurements, 10 patients lacked
hscTnI measurements, 3 patients lacked sNGAL measurements, and 92 patients lacked uNGAL measurements on
admission; these patients were excluded. A total of 787
patients were included in this analysis.

Specimen Collection

Serum samples for biomarker assessment were collected
with ethylenediaminetetraacetic acid plasma tubes, processed to plasma, frozen, and shipped to the core laboratory.
Urine samples were centrifuged, frozen, and shipped to the
core laboratory. Serum and urine specimens were collected
up to 6 times, depending on the hospitalization duration.
The first specimen was collected on the day of enrolment
within 2 hours of the first intravenous diuretic dose. The
second specimen was collected 2 6 hours later. The third,
fourth, and fifth specimens were collected on hospital days
1, 2, and 3, respectively. The sixth specimen was collected
on the day of discharge or anticipated discharge. uNGAL
Table 1. Baseline Characteristics in Patients With or Without
Nonsevere WRF
WRF
(n = 193)
Age (years)
70 § 14
Male sex
123 (64)
White race
379 (64)
History of CAD
102 (53)
History of hypertension
165 (86)
History of hyperlipidemia
107 (55)
History of diabetes
99 (51)
mellitus
History of COPD
44 (23)
History of CKD
62 (32)
Tobacco use
29 (15)
ACE-I
83 (43)
ARB
40 (21)
b-Blocker
140 (73)
Diuretics
128 (66)
Systolic BP (mm Hg)
146 § 31
Heart rate (bpm)
87 § 22
Edema
147 (76)
Rales present
87 (45)
Sodium (mEq/L)
139 § 5
Hemoglobin (g/dL)
11.2 [9.5 12.8]
BUN (mg/dL)
28 [20 44]
Creatinine (mg/dL)
1.35 [1.00 1.80]
2
50 [36 68]
eGFR (mL/min/1.73 m )
BNP (ng/l)
646 [285 1119]
hscTnI (ng/l)
31.9 [16.5 79.2]
Gal3 (ng/mL)
26.6 [21.3 37.6]
sNGAL (ng/mL)
170.4
[107.0 329.5]
uNGAL (ug/g)
38.1 [15.1 78.7]

No WRF
(n = 594)
68 § 14
376 (63)
124 (64)
260 (44)
470 (79)
301 (51)
246 (41)
159 (27)
139 (23)
99 (17)
263 (44)
111 (19)
417 (70)
430 (72)
139 § 29
88 § 23
441 (74)
248 (42)
138 § 7
12.0 [10.4 13.3]
23 [16 33]
1.15 [0.92 1.50]
60 [43 82]
509 [206 1108]
23.9 [12.2 54.6]
24.5 [19.2 34.6]
123.9
[76.7 219.6]
23.1 [12.1 59.8]

P value
.081
.982
.980
.034
.065
.285
.020
.317
.020
.671
.822
.603
.597
.128
.003
.720
.661
.466
.546
<.001
<.001
<.001
<.001
.029
.001
.010
<.001
.001

ACE-I, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II
receptor blocker; BNP, B-type natriuretic peptide; BP, blood pressure;
CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration
rate; Gal3, galectin 3; hscTnI, high sensitivity cardiac troponin I; sNGAL,
serum neutrophil gelatinase-associated lipocalin; uNGAL, urine neutrophil
gelatinase-associated lipocalin; WRF, worsening renal function.
Values are mean § standard deviation, number (%), or median [interquartile range].
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was indexed to urine creatinine to account for urine tonicity.
Levels of serum creatinine were measured each day during
hospitalization.

limit of detection (LLD) of these assays are as follows:
BNP, CV less than 12%, LLD 10 ng/L; hscTnI, CV less
than 10%, LLD 1.1 1.9 ng/L; Gal3 less than 10%, LLD
1.0 ng/mL; sNGAL, CV 2.1%, LLD 0.7 ng/mL; uNGAL,
CV 3.1%, LLD 0 ng/mL.

Biomarker Assessment

Specimens were analyzed at the core laboratory with the
Alere Triage platform for sNGAL and ARCHITECT platform (Abbott Laboratories) for BNP, hscTnI, Gal3, and
uNGAL. The coefficient of variance (CV) and the lower

Clinical End Point

The end points were WRF and a composite of 1-year
mortality or HF hospitalization. Mortality and HF

Fig. 1. (A) Correlations of absolute and relative changes in biomarkers and creatinine. (AI) Absolute changes in biomarkers and creatinine.
(AII) Relative changes in biomarkers and creatinine. Absolute (AI) and relative (AII) changes in serum creatinine were weakly correlated
with those in BNP, Gal3, and sNGAL, and were not correlated with hscTnI and uNGAL. BNP, B-type natriuretic peptide; Gal3, galectin 3;
hscTnI, high sensitivity cardiac troponin I; uNGAL, urine neutrophil gelatinase-associated lipocalin; sNGAL, serum neutrophil gelatinaseassociated lipocalin. (B) Prediction of WRF with admission values of biomarkers. AUCs of admission values of biomarkers for predicting
WRF were poorly discriminatory, with highest AUC of 0.62 and were not better than admission serum creatinine. AUC, area under the
receiver operating curve; BNP, B-type natriuretic peptide; Gal3, galectin 3; hscTnI, high sensitivity cardiac troponin I; uNGAL, urine neutrophil gelatinase-associated lipocalin; sNGAL, serum neutrophil gelatinase-associated lipocalin; WRF, worsening renal function.
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Fig. 1 Continued.

hospitalization were also analyzed individually. WRF was
defined as an increase in creatinine of greater than or equal
to 0.3 mg/dL or 50% from the first creatinine during the first
5 days. This definition was chosen because it is the most
commonly used in literature.1

admission values of biomarkers for predicting WRF. Relationships between biomarkers and WRF were also investigated using multivariable logistic regression analysis, with
each biomarker adjusted for risk factors for WRF including
age, gender, history of hypertension, diabetes mellitus, coronary artery disease (CAD), creatinine, and hemoglobin,
which have previously been identified in a meta-analysis.1
Diuretic use was not included, because AKINESIS enrolled
patients who must have received or planned treatment with
intravenous diuretics, and 780 patients (99%) included in
the current analysis received diuretic therapy. A model only
adjusting for biomarkers was also analyzed. Log-rank,
Kaplan Meier, and Cox analyses were used to investigate
the relationship between WRF and clinical outcomes. We
evaluated the risk of 1-year outcomes in patients with combinations of WRF and changes in biomarkers with change
analyzed using tertiles of relative changes from admission
to peak values during the first 3 days of hospitalization. For
BNP, the lowest value was used, considering the previous
study investigating a relationship between BNP decrease
and WRF.17 In the multivariable Cox analysis, WRF was
adjusted for clinical variables and admission values of biomarkers. Clinical variables included age, race, history of
chronic obstructive disease, edema, systolic blood pressure,
heart rate, sodium, hemoglobin, and blood urea nitrogen
based on prior studies.18 22 BNP, hscTnI, Gal3, sNGAL,
uNGAL, and creatinine were log-2 transformed so that each
increase represents a doubling in the value. All statistical
analyses were performed using R x64 3.6.3 for Windows.

Statistical Analysis

Results

Continuous variables were described as means with standard deviations, or medians with interquartile ranges if nonnormally distributed. Categorical variables were described
as counts and percentages. The Student t test, Mann Whitney U test, and x2 test were used for group comparison as
appropriate. Relationships between absolute and relative
changes from admission to day 2 or 3 in creatinine and other
biomarkers were analyzed using Spearman’s correlation
coefficient. The area under the receiver operating characteristic curves were used to investigate the usefulness of

Patient Characteristics

Of the 787 patients included, the mean age was 68 §
14 years, 63% were male, 46% had a history of CAD, and
44% had a history of diabetes mellitus. A history of chronic
kidney disease was reported in 26%, with a median serum
creatinine and estimated GFR on admission of 1.19 mg/dL
(interquartile range, 0.93 1.59 mg/dL) and 57 mL/min/
1.73 m2 (interquartile range, 41 79 mL/min/1.73 m2),
respectively.

Table 2. Logistic Regression Analysis for WRF

BNP
hscTnI
Gal3
sNGAL
uNGAL
Creatinine

OR

Univariable
95% CI

1.12
1.15
1.27
1.41
1.13
1.64

1.02
1.06
1.02
1.22
1.04
1.27

1.23
1.26
1.58
1.61
1.22
2.13

P Value

OR

.022
<.001
.035
<.001
.004
<.001

1.08
1.13
1.00
1.28
1.07

Multivariable model 1
95% CI
0.97
1.03
0.76
1.08
0.98
—

1.19
1.23
1.30
1.51
1.17

P Value

OR

Multivariable model 2
95% CI

.157
.009
.972
.004
.123

1.07
1.12
0.94
1.36
1.06
1.04

0.96
1.02
0.71
1.14
0.97
0.74

1.19
1.23
1.23
1.62
1.16
1.47

P Value
.235
.015
.639
<.001
.180
.822

Model 1. Each biomarker was adjusted for age, gender, history of hypertension, diabetes mellitus, coronary artery disease, creatinine and hemoglobin
Model 2. Only biomarkers are included.
CI, confidence interval; OR, odds ratio. Other abbreviations as in Table 1.
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Fig. 2. WRF and 1-year clinical outcomes. (A) Death or heart failure hospitalization within 1 year. (B). Death within 1 year. (C). Heart failure hospitalization within 1 year. WRF was not associated with any clinical outcomes at 1 year. WRF, worsening renal function.
Characteristics of Patients With WRF

WRF occurred in 193 patients (25%). Patients with WRF
more frequently had a history of CAD, diabetes mellitus,
and chronic kidney disease and had higher systolic blood
pressure on admission (Table 1). WRF was associated with
higher levels of creatinine and blood urea nitrogen, and
lower levels of hemoglobin and estimated GFR on admission. Levels of all biomarkers on admission were higher in
those with WRF.
Biomarkers for Predicting WRF

During the second or third day of hospitalization, absolute and relative changes in serum creatinine were weakly
correlated with those in BNP, Gal3, and sNGAL, but were
not correlated with hscTnI or uNGAL (Fig. 1A). The areas
under the receiver operating curve of admission values of
biomarkers for predicting WRF were poorly discriminatory
with the highest area under the receiver operating curve of
0.62, and were not better than admission serum creatinine

(Fig. 1B). In multivariable logistic regression analysis, the
admission values of hscTnI and sNGAL were significantly
associated with WRF after adjustment for confounders
(Table 2).

Biomarkers and WRF for Predicting Outcomes

During follow-up, 139 patients (18%) died and 154
patients (20%) were hospitalized because of HF; 260
patients (33%) developed the composite of death or HF hospitalization at 1 year. WRF did not predict the composite
end point and HF hospitalization at 1 year (Fig. 2). The
admission BNP was associated with all 1-year outcomes,
hscTnI was associated with the composite end point and
mortality, and Gal3 was associated with mortality after
adjustment for clinical variables and biomarkers (Table 3).
None of the biomarkers modified the risk of WRF for the
composite outcome and death (Fig. 3A and 3B). However,
patients with WRF in the higher tertiles of the ratio of peak
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Table 3. Cox Analysis for Clinical Outcomes at the 1-Year
Composite End Point
HR

95% CI

P Value

1.01

0.76 1.35

.934

1.03

0.77 1.38

.828

0.99
1.23
1.08
1.09
1.04
0.98

0.73
1.13
1.01
0.89
0.92
0.92

1.33
1.33
1.16
1.34
1.18
1.05

.93
<.001
.018
.423
.506
.583

1.16

0.80 1.69

.439

1.10

0.74 1.62

.64

1.06
1.24
1.12
1.61
1.03
0.96

0.71 1.57
1.1 1.39
1.03 1.22
1.26 2.06
0.88 1.22
0.88 1.05

.793
<.001
.012
<.001
.708
.368

0.95

0.65 1.38

.783

0.98

0.67 1.44

.928

0.99
1.21
0.99
0.87
1.02
0.97

0.67 1.47
1.09 1.35
0.9 1.08
0.66 1.14
0.87 1.2
0.88 1.06

.966
<.001
.794
.300
.775
.469

Univariable model
WRF
Multivariable model 1
WRF
Multivariable model 2
WRF
BNP
hscTnI
Gal3
sNGAL
uNGAL
Death
Univariable model
WRF
Multivariable model 1
WRF
Multivariable model 2
WRF
BNP
hscTnI
Gal3
sNGAL
uNGAL
Heart failure hospitalization
Univariable model
WRF
Multivariable model 1
WRF
Multivariable model 2
WRF
BNP
hscTnI
Gal3
sNGAL
uNGAL

Multivariable model 1 is adjusted for age, Black race, history of chronic
obstructive disease, oedema, systolic blood pressure, heart rate, sodium,
hemoglobin, and blood urea nitrogen.
Multivariable model 2 is adjusted for factors included in model 1 and
BNP, hscTnI, sNGAL, uNGAL, and Gal3.
HF, heart failure; HR, hazard ratio. Other abbreviations as in Tables 1
and 2.

to admission uNGAL had a higher incidence of HF hospitalization (Fig. 3C).
Discussion
In this subanalysis of AKINESIS, we evaluated whether
biomarkers reflective of systemic pathophysiologic processes in AHF and potentially CRS can predict and discriminate WRF. Changes in biomarkers and creatinine
were not well correlated, and the admission values of biomarkers were not able to predict WRF better than serum
creatinine. hscTnI and sNGAL were independent predictors of WRF. WRF was not associated with 1-year outcomes after adjusting for clinical variables; however,
biomarkers were associated with 1-year clinical outcomes
and patients with WRF and increasing uNGAL had an
increased risk of HF hospitalization.
Given the reported variability in the clinical significance
of WRF in AHF, studies have been trying to discriminate

the impact of AHF on kidney health using biomarkers of
ATI.5,7,23,24 These studies have overall found a lack of predictive usefulness of ATI biomarkers for WRF, largely
owing to a dissociation between renal functional change
and injury. NGAL (both serum and urine), N-acetyl-b-dglycosaminidase, and kidney injury molecule 1 have repeatedly failed to show these biomarkers can predict impending
WRF.5,23,24 However, these studies are looking at the endorgan damage of AHF on the kidney and, if injury does
occur, they may not capture the systemic pathophysiologic
processes behind WRF. Our study examined CRS by evaluating systemic dysfunction from AHF as reflected by biomarkers of congestion, myocardial damage, kidney injury,
inflammation, and fibrosis. These systemic processes in
AHF similarly impact the kidney, contributing to hemodynamic perturbations that decrease the driving force for fluid
and salt excretion in the kidney, and neurohormonal activation and immune-mediated damage that lead to kidney
injury and fibrosis.6,25 28
Despite capturing a broad spectrum of pathophysiologic
process, none of the individual admission biomarker values
predicted subsequent WRF better than serum creatinine, and
changes in these biomarkers were not meaningfully correlated with creatinine. This outcome is likely because no single pathophysiologic process causes CRS in AHF, but WRF
is a culmination of the various processes measured in this
study, as well as others that were unmeasured. In the multivariate analysis as well, most of the biomarkers were not significant for developing WRF. Intriguingly, admission hscTnI
significantly predicted an increased odds of WRF, suggesting
the presence of myocardial injury in AHF may translate to a
more severe impact of AHF on the kidney. Of note, patients
presenting with acute coronary syndrome and AHF were
excluded from enrolment in the AKINESIS study. The relationship between hscTnI and WRF may not simply be the
result of reduced hscTnI clearance with impaired renal function, because the multivariable model included serum creatinine. Myocardial injury reflected by elevated troponin in
AHF is thought to result from numerous different processes
including CAD, demand ischemia, microvascular dysfunction, myocardial stretch, inflammation, and oxidative
stress.12 These systemic processes could concurrently be
impacting the kidney. This finding expands on the already
described prognostic usefulness of hscTn in AHF for mortality to now potentially include prognostic usefulness of the
systemic impact of myocardial injury on AHF.
Although admission sNGAL was associated with WRF,
this finding may not be indicative of the kidney injury
occurring with WRF, because sNGAL can reflect systemic
inflammation and decreased glomerular filtration of NGAL
from extrarenal sources, in addition to renal tubular
injury.13 15 If kidney injury was associated with WRF, we
would have expected to see similar or even greater findings
with uNGAL, which is more specific for kidney injury,
given its inducible production at the site of injury.14
Conflicting findings regarding the impact of WRF on outcomes have been reported, which is likely because of the
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Fig. 3. Risk for 1-year clinical outcomes by biomarker tertiles in patients with WRF. (A) Death or heart failure hospitalization within 1
year. (B) Death within 1 year. (C) Heart failure hospitalization within 1 year. The risk of 1-year clinical outcomes in patients with combinations of WRF and changes in biomarkers was analyzed. Changes in biomarkers were evaluated using tertiles of relative changes from admission to peak values during the first 3 days of hospitalization. For BNP, the lowest value was used. None of the biomarkers modified the risk
of WRF for the composite outcome and death (A and B). WRF in higher tertiles of the ratio of peak to admission uNGAL had a higher incidence of heart failure hospitalization (C). BNP, B-type natriuretic peptide; Gal3, galectin 3; hscTnI, high sensitivity cardiac troponin I;
uNGAL, urine neutrophil gelatinase-associated lipocalin; sNGAL, serum neutrophil gelatinase-associated lipocalin; WRF, worsening renal
function.

heterogeneity of mechanisms causing WRF.1 5 There has
been a growing appreciation for the mechanisms causing
WRF in determining the clinical impact and prognostic significance of WRF. In the current analysis, in contrast with
WRF, biomarkers such as BNP, hscTnI, and Gal3 were
associated with clinical outcomes. Biomarkers reflecting
severity of congestion, myocardial injury, fibrosis, and
inflammation, which are proposed pathophysiologic processes of CRS in AHF, were able to predict 1-year clinical
outcomes beyond WRF.6 This finding supports the hypothesis that the pathophysiologic mechanisms driving WRF
determine the clinical significance.
Despite the general lack of prognostic significance of
WRF and uNGAL in our study, this result should not be
interpreted as finding that CRS in AHF is not clinically
meaningful. We demonstrated that patients with WRF
who experienced greater increases in uNGAL from admission were more likely to experience HF hospitalization
within 1 year. This finding may indicate that WRF with

substantial kidney injury is a more clinically meaningful
form of kidney dysfunction. One hypothesis is that those
experiencing substantial renal tubular injury may not
respond well to diuretic therapy and may become more
likely to reaccumulate fluid and be readmitted. Considering the relatively high blood pressure on admission in
patients with WRF and the lack of prognostic impact of
WRF with elevated uNGAL on mortality, WRF with kidney injury seems less likely to be due to impaired renal
perfusion with low output syndrome, which is generally
associated with low blood pressure and a poor prognosis.
Thus, WRF patients with elevated uNGAL have features
less consistent with an increased risk of mortality, but
more likely to present with other events, such as HF readmission. Although other markers did not improve prognostication of WRF, further research is required to investigate
the pathophysiologic process behind WRF through hemodynamic and nonhemodynamic contributors, incorporating
various clinical findings as well as biomarker values to
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refine and identify patients with WRF who are at high risk
for adverse outcomes.
Limitations
Although this is one of the largest cohort studies investigating cardiorenal biomarker trajectories in AHF patients,
the lack of a urine sample in 92 patients may have affected
the results. Our study is a post hoc analysis of a prospective
AHF cohort; thus, the result is only hypothesis generating,
and unmeasured confounding factors need to be considered
in the multivariable analysis. Biomarker collection beyond
the first few days of hospitalization may have found other
significant trends not captured in the current analysis.
Unfortunately, AKINESIS did not include serial measurements of hemodynamic parameters such as blood pressure,
physical findings of congestion, or invasive hemodynamic
monitoring.
Conclusions
Among patients with AHF treated with diuretic therapy,
biomarkers were not able to predict WRF better than serum
creatinine. One-year outcomes were associated with different
pathophysiologic biomarkers, but not with WRF. Patients
with WRF and increasing uNGAL during hospitalization had
an increased risk of HF hospitalization within 1 year.
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